A perfusion loop assembly for ex vivo liver perfusion includes a pump providing perfusion fluid through a line branching at a branching point into a first branch line and a second branch line. The first branch line provides a first portion of the perfusion fluid to the hepatic artery of the liver, the first branch line coupled with a gas exchanger, where the first branch line includes a flow rate sensor and/or a pressure sensor. The second branch line provides a second portion of the perfusion fluid to the portal vein of the liver; the second branch line includes a valve for controlling flow of perfusion fluid into the portal vein. The second branch line includes a flow rate sensor and/or a pressure sensor. A liver chamber assembly holds the liver ex vivo, and an outlet line for the perfusion fluid connects the liver chamber assembly and the pump.

A perfusion loop assembly for ex vivo liver perfusion includes a pump providing perfusion fluid through a line branching at a branching point into a first branch line and a second branch line. The first branch line provides a first portion of the perfusion fluid to the hepatic artery of the liver, the first branch line coupled with a gas exchanger, where the first branch line includes a flow rate sensor and/or a pressure sensor. The second branch line provides a second portion of the perfusion fluid to the portal vein of the liver; the second branch line includes a valve for controlling flow of perfusion fluid into the portal vein. The second branch line includes a flow rate sensor and/or a pressure sensor. A liver chamber assembly holds the liver ex vivo, and an outlet line for the perfusion fluid connects the liver chamber assembly and the pump.

Provided herein are formulations and methods for the stabilization of one or more thrombocytes at ambient temperatures. Also provided are formulations and methods for the stabilization of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures. Further provided are articles of manufacture and kits and methods for substantially stable storage of one or more thrombocyte at ambient temperatures.

Provided herein are formulations and methods for the stabilization of one or more thrombocytes at ambient temperatures. Also provided are formulations and methods for the stabilization of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures. Further provided are articles of manufacture and kits and methods for substantially stable storage of one or more thrombocyte at ambient temperatures.

Due to a rising demand in the need for organ transplantation and a critical donor organ shortage, the need to fill this gap has increased the use of ECD and donation after cardiac death (DCD) organs viable for transplantation to lower the mortality of patients on the organ waiting list. Described herein is a perfusion solution comprising polymerized hemoglobin, wherein the perfusion solution comprises less than 5% by weight low molecular weight hemoglobin species, based on the total weight of the perfusion solution.

Due to a rising demand in the need for organ transplantation and a critical donor organ shortage, the need to fill this gap has increased the use of ECD and donation after cardiac death (DCD) organs viable for transplantation to lower the mortality of patients on the organ waiting list. Described herein is a perfusion solution comprising polymerized hemoglobin, wherein the perfusion solution comprises less than 5% by weight low molecular weight hemoglobin species, based on the total weight of the perfusion solution.

Provided are a cryopreservation liquid for bovine reproductive cells such as bovine sperms and a cryopreservation method thereof. Adopted is a cryopreservation liquid comprising: 0.3 to 0.9 w/w % of an amphoteric polyelectrolyte (an antifreeze polyamino acid), which is -poly-L-lysine having a number average molecular weight of 1,000 to 20,000 wherein 50 to 99 mol % of amino groups of the -poly-L-lysine are blocked as carboxylated by having been reacted with the succinic anhydride; and 2 to 4 w/w % of glycerol, as dissolved in a physiological solution. A preferred embodiment of the cryopreservation method comprises steps of: primary diluting, in which bovine semen is diluted to 2.5 to 10 times with a physiological solution and kept at 2 to 8 C.; and secondary diluting, in which the bovine semen is diluted to 5 to 20 times while being kept at 2 to 8 C., by adding dropwise a physiological solution containing the amphoteric polyelectrolyte (antifreeze polyamino acid) and glycerol to a suspension obtained in the primary diluting.

Provided are a cryopreservation liquid for bovine reproductive cells such as bovine sperms and a cryopreservation method thereof. Adopted is a cryopreservation liquid comprising: 0.3 to 0.9 w/w % of an amphoteric polyelectrolyte (an antifreeze polyamino acid), which is -poly-L-lysine having a number average molecular weight of 1,000 to 20,000 wherein 50 to 99 mol % of amino groups of the -poly-L-lysine are blocked as carboxylated by having been reacted with the succinic anhydride; and 2 to 4 w/w % of glycerol, as dissolved in a physiological solution. A preferred embodiment of the cryopreservation method comprises steps of: primary diluting, in which bovine semen is diluted to 2.5 to 10 times with a physiological solution and kept at 2 to 8 C.; and secondary diluting, in which the bovine semen is diluted to 5 to 20 times while being kept at 2 to 8 C., by adding dropwise a physiological solution containing the amphoteric polyelectrolyte (antifreeze polyamino acid) and glycerol to a suspension obtained in the primary diluting.

A method of preserving a donor heart, comprising perfusing the donor heart with oxygenated blood-based perfusate, wherein the donor heart is predominantly kept in non-beating state.

The present invention relates to the preservation of collagenous connective tissue so as to achieve the structural integrality of the collagen fibers, rendering the tissue suitable for use in implants without causing immune and/or inflammatory rejection, comprising the steps of trimming the collagenous connective tissue in a buffer solution, washing the connective tissue with the buffer solution, stabilizing the tissue in an ethanol solution, treating the tissue with polyethylene glycol solution and hydrogen peroxide, washing and storing the tissue in ethanol, sterilizing the tissue with an ethanol and hydrogen peroxide solution and storing the tissue for transport in ethanol and indomethacin solution. The preferred use of the present invention is in surgical interventions for correcting various anomalies of the human body, where the graft is particularly required.